Evidence map›Paper›PMID 31919120›Full record

ArticleCancer discovery2020

Can the Help Match the Hype? KRAS

Samuel J Klempner, Aaron N Hata

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Covalent inhibitor targets KRasGenes & diseases · 2023
    Review
  3. Review
  4. Review
  5. Review
  6. Overcoming Resistance to Drugs TargetingInnovation (Cambridge (Mass.)) · 2020
    Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Samuel J KlempnerDivsion of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. sklempner@partners.org.ORCID https://orcid.org/0000-0002-4062-0808
Aaron N HataDivsion of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hallin and colleagues demonstrate the preclinical activity of the KRAS

Indexed as

Antineoplastic AgentsProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorDisease Models, AnimalHumansMiceMutationAntineoplastic AgentsKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID31919120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.